Tenaya Therapeutics Chief Medical Officer Tingley Whittemore sold a total of 7,424 shares of common stock on August 17, 2026, for a combined value of $5,267. The shares were sold at prices ranging from $0.6820 to $0.7253. Following these reported transactions, Whittemore beneficially owns 214,073 shares of Tenaya Therapeutics common stock.
Recent News
Tenaya Therapeutics Inc. reported interim safety and efficacy data from its MyPEAK-1 Phase 1b/2 clinical trial, evaluating the TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. The company also announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026.